|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Irbesartan#Adult Indications and Dosage]] |
| {{Irbesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ===Hypertension===
| |
| | |
| AVAPRO (irbesartan) is indicated for the treatment of [[hypertension]]. It may be used alone or in combination with other [[antihypertensive agents]].
| |
| | |
| ===Nephropathy in Type 2 Diabetic Patients===
| |
| | |
| AVAPRO is indicated for the treatment of [[diabetic nephropathy]] with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and [[hypertension]]. In this population, AVAPRO reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see CLINICAL PHARMACOLOGY: Clinical Studies).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98 | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Sanofi]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Lactams]]
| |
| [[Category:Spiro compounds]]
| |
| [[Category:Nitrogen heterocycles]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |